丹参酮ⅡA对急性心肌梗死无复流作用研究  

Effect of administration of tanshinone ⅡA on the no-reflow in patients with acute myocardial infarction

作　　者：郭张强[1] 成忠[1] 李论[1] 吴婕[1] 白玉鹏[1] 刘启云[1] 李刚[1] 顾晔[1] 

机构地区：[1]华中科技大学同济医学院附属普爱医院心内科,武汉430033

出　　处：《临床心血管病杂志》2011年第3期184-186,共3页Journal of Clinical Cardiology

摘　　要：目的:通过研究丹参酮ⅡA注射液对急性心肌梗死(AMI)患者无复流的影响,探讨丹参酮ⅡA干预冠状动脉无复流的免疫调节机制。方法:应用酶联免疫吸附实验、倒置显微镜检测30例稳定型心绞痛对照组和88例AMI患者(无复流+丹参酮ⅡA治疗组28例,无复流无丹参酮ⅡA治疗组20例,有复流不用丹参酮ⅡA治疗组40例)治疗后第4周检测外周血的血清细胞因子和外周血内皮祖细胞计数。结果:与对照组相比,AMI患者血清细胞因子和外周血内皮祖细胞计数都显著减少,但是有复流不用丹参酮ⅡA治疗组、无复流+丹参酮ⅡA治疗组的二者减低程度明显小于无复流无丹参酮ⅡA治疗组。结论:丹参酮ⅡA调节AMI无复流患者的细胞因子和内皮祖细胞,在无复流中具有免疫调节作用。Objective：To study the effects of tanshinone ⅡA on the no-reflow in patients with AMI,and therefore,provide new theory for the immunoregulation mechanism of tanshinone ⅡA in the AMI.Method：We prospectively studied 88 patients underwent acute myocardial infarction,who were random designated to no-reflow treated with tanshinone ⅡA group（28 cases） or without tanshinone ⅡA group（20 cases） and reflow without tanshinone ⅡA treated group（40 cases）.The stable angina pectoris（30 cases） group was designated to the control group.TGF-β1 and the number of colony-forming units of endothelial progenitor cell（EPC） in the peripheral blood were measured on 4 weeks by ELISA and counted by phase-contrast microscope,respectively.Result：The level of TGF-β1 and EPC number in the AMI group were significantly lower than those in control group（P0.05）,and there was statistical difference between the no-reflow group and reflow group.The amelioration of the decreased TGF-β1 level and EPC number in the no-reflow treated group and refolw group were significantly lower than those in the no-reflow without tanshinone ⅡA group（P0.05）.Conclusion：Regulation of TGF-β1 and EPC by tanshinone ⅡA,suggesting a possible mechanism of tanshinone ⅡA in the immunoregulation role in the no-reflow phenomenon in the AMI.

关 键 词：心肌梗死 丹参酮ⅡA 无复流 内皮祖细胞 

分 类 号：R542.2[医药卫生—心血管疾病]